Kaletra combination tablets ( Lopinavir Ritonavir HIV)

General information on Kaletra tablets (Lopinavir+Ritonavir combination)

Package details: 120 tablets

Manufacturer: AbbVie GK, Japan

Active ingredient: Lopinavir 200 mg, Ritonavir 50 mg in each tablet

Medical effect: Kaletra combination tablets are effective for the following procedures:

1. inhibiting HIV virus growth,
2. inhibitiing of HIV protease activity,
3. increasing the level of lopinavir in human blood,
4. increasing CD4 cell in the blood plasma.

Contraindications and precautions: do not use for pregnant or breastfeeding women. Do not use in patients with renal or liver failure or in patients taking colchicine. If an allergic reaction occurs, stop using the medication and consult with your doctor. If you’re taking any other medication, consult with your doctor before use because drug incompatibility is possible.

Dosage and administration of Japanese Kaletra combination tablets       

For adults: take 2 tablets 2 times a day or 4 tablets once a day depending on you doctor's prescription.

For children or adults with weight below 40 kg: take 2 tablets 2 times a day.

The consulting doctor may adjust the dosage according to age and symptoms.

How effective are Japanese Kaletra combination tablets for HIV treatment?

The effect of this antiviral drug is based on human immunodeficiency virus protease inhibitors. Thanks to protease inhibition, complete protein synthesis becomes impossible, and the virus becomes immature and incapable of further infection. Thus, combination pills inhibit the growth of HIV viruses and stop progressive diseases. The combination of lopinavir and ritonavir has a strong antiviral effect, and also increases the residence time and amount of active substances in the blood plasma.

The US National Medical Base has more than two hundreds researches on the effect and use of this medicine. For example, in one study perforemed over 6 years, more than 1000 patients who have already failed treatment with other antiviral drugs and develop resistance were given combination tablets of lopinavir and ritonavir. (X. Xuang, L. Xu et al. Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China. Frontiers in pharmacology, 2019 (11), Dec.). Even among such difficult patients, a healthy amount of CD4 cells in the blood was completely restored in 37.2% of patients, and when taking the drug for a year or more, the virus suppression rate exceeded 90%.